Weer geen wonderpil. (Dutch/Flemish)

De Europese geneesmiddelencommissie trok onlangs de registratie van 'afvalpil' rimonabant in, omdat post-marketingonderzoek neuropsychiatrische bijwerkingen liet zien. De fabrikant beëindigde kort daarop onderzoek naar de effecten van rimonabant op het cardiovasculaire risicoprofiel. [ABSTRACT FROM AUTHOR]

Copyright of Huisarts En Wetenschap is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)